Rapid low cost formulation screening for protein self-interaction based on High Performance Capillary Electrophoresis

基于蛋白质的生物制药的进步代表了制药行业最具创新性和利润丰厚的发展。单克隆抗体的治疗已经从以前的高死亡率疾病如癌症发展到现代的慢性疾病，包括阿尔茨海默病，狼疮，糖尿病和慢性疼痛。随着对生物制药产品需求的增加，由于蛋白质自身相互作用而导致的蛋白质聚集（粘在一起）仍然是制剂中的巨大挑战。我们提出的可行性研究解决了对具有成本效益，用户友好，自动化平台技术的需求，该技术可以快速筛选蛋白质自我相互作用。我们提出的平台技术的成功开发和商业化不仅将为制药行业带来大量成本节约，而且有可能通过采用创新的药物输送系统释放医院资源并改善患者体验。

The advance in protein-based biopharmaceuticals represents the most innovative and lucrative development in the pharmaceutical industry. Treatment with mAbs has evolved from former high mortality diseases like cancer into modern day chronic illness, including Alzheimer’s disease, lupus, diabetes and chronic pain. With the increased need for biopharmaceutical products, protein aggregation (sticking together) due to protein self-interaction remains a enormous challenge in formulation. Our proposed feasibility study addresses the need for a cost-effective, user-friendly, automated platform technology that allows rapid screening for protein self-interactions. The successful development and commercialisation of our proposed platform technology will not only bring substantial cost savings to the pharmaceutical industry but also has the potential to free up hospital resource and improve patient experience by adopting innovative drug delivery systems.